Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients

NCT06778538 | Completed

• 1 other identifier: 2023A-096
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the role of HPGD in clear cell renal cell carcinoma (ccRCC). Specifically, it will focus on HPGD's impact on proliferation, epithelial-mesenchymal transition (EMT), and prognosis. The study will analyze gene expression data from clinical samples and use techniques like RT-qPCR, Western blotting, and immunohistochemistry to assess HPGD expression levels. Additionally, the research will explore the relationship between HPGD and patient survival outcomes. By elucidating HPGD's contribution to cancer progression, the study seeks to identify potential therapeutic targets for improving renal cancer treatment.

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)

Keywords

HPGD; clear cell renal cell carcinoma; biomarker; prognosis; EMT; tumorigenesis; SLCO2A1

Outcome Measures

Primary Outcomes (1)

• HPGD Expression Levels in clear cell renal cell carcinoma（ccRCC） Patients

  The primary outcome will measure the expression levels of HPGD in ccRCC tissues compared to adjacent normal tissues, and its correlation with clinical outcomes such as overall survival (OS) and progression-free survival (PFS).

  2024.1-2024.6

Interventions

Immunohistochemistry; WB; PCR DIAGNOSTIC_TEST

The intervention will specifically focus on evaluating the role of HPGD in patients with clear cell renal cell carcinoma by classifying them into high-low expression groups based on median HPGD expression values by immunohistochemical scores for prognostic analysis. Protein and RNA were extracted from collected ccRCC tissues for expression verification.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of adult patients aged 18 years or older with a confirmed diagnosis of clear cell renal cell carcinoma. Participants will be recruited from oncology clinics and hospitals, and all eligible individuals must have measurable disease as defined by RECIST criteria. Both male and female participants will be included, with no restrictions based on ethnicity or socioeconomic background. Participants will be required to provide informed consent and meet the inclusion criteria related to health status and prior treatments.

You may qualify if:

• Adults aged 18 years or older. Histologically confirmed diagnosis of clear cell renal cell carcinoma . Measurable disease as per RECIST criteria. Adequate organ function as defined by laboratory tests (e.g., liver, kidney, and hematologic function).
• HPGD expression level determined via biopsy or previous analysis. Written informed consent provided.

You may not qualify if:

• History of other malignancies within the past 5 years, excluding non-melanoma skin cancer or in situ carcinoma.
• Prior treatment with HPGD inhibitors or similar targeted therapies. Active or uncontrolled infections. Pregnant or breastfeeding women. Known autoimmune disorders or conditions requiring immunosuppressive therapy. Inability to comply with the study protocol or procedures.

Sponsors & Collaborators

• Shang Panfeng: lead
• Lanzhou University Second Hospital: collaborator

Study Sites (1)

Lanzhou University Second Hospital

Lanzhou, Gansu, 730000, China

Location

Related Publications (4)

• Monteleone NJ, Moore AE, Iacona JR, Lutz CS, Dixon DA. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer. Sci Rep. 2019 Apr 1;9(1):5405. doi: 10.1038/s41598-019-41862-2.

  PMID: 30931980 BACKGROUND

• Arima K, Komohara Y, Bu L, Tsukamoto M, Itoyama R, Miyake K, Uchihara T, Ogata Y, Nakagawa S, Okabe H, Imai K, Hashimoto D, Chikamoto A, Yamashita YI, Baba H, Ishimoto T. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1beta from activated macrophages leads to poor prognosis in pancreatic cancer. Cancer Sci. 2018 Feb;109(2):462-470. doi: 10.1111/cas.13467. Epub 2018 Jan 27.

  PMID: 29224225 BACKGROUND

• Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12098-102. doi: 10.1073/pnas.0603235103. Epub 2006 Jul 31.

  PMID: 16880406 BACKGROUND

• Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, Koeffler HP. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006 Aug 1;66(15):7818-23. doi: 10.1158/0008-5472.CAN-05-4368.

  PMID: 16885386 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Tissue samples, blood samples, and other relevant biological specimens will be retained for future analysis, including potential DNA extraction for genetic studies.

MeSH Terms

Conditions

Carcinoma, Renal Cell; Carcinogenesis

Interventions

Immunohistochemistry

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Histocytochemistry; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Histological Techniques; Investigative Techniques; Immunologic Techniques

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 11, 2025
• First Posted: January 16, 2025
• Study Start: July 1, 2024
• Primary Completion: November 1, 2024
• Study Completion: November 20, 2024
• Last Updated: January 16, 2025

Record last verified: 2025-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)